Novo Seeds invests €2.7M in Antag

Metabolic start-up Antag Therapeutics ApS (Copenhagen, Denmark) said it has received a €2.7 million ($3 million) investment from Novo Seeds, the early stage investment arm of Novo Holdings A/S (Hellerup, Denmark).

Antag is developing peptide therapeutics to treat dietary-related metabolic diseases such as obesity, Type II diabetes and fatty liver disease. It is a spinout of the University of Copenhagen and has been incubated by Novo Seeds since 2014...